Metabolic syndrome correlates with significantly adverse disease outcomes in COVID-19 patients during the second wave of pandemic

Khushbu Ruparel; Ankita Priyadarshini; Mrugesh Suthar; Ajit K. Gangawane; Hemantkumar Patadia

doi:10.53730/ijhs.v6nS6.9794

Authors

Khushbu Ruparel M.Sc. MLT, Department of Paramedical and Health Sciences, Faculty of Medicine, Parul University, Vadodara-391760, Gujarat, India
Ankita Priyadarshini PhD Scholar, Department of Microbiology, Faculty of Applied Sciences, Parul University, Vadodara-391760, Gujarat, India | Assistant Professor, Department of Paramedical and Health Sciences, Faculty of Medicine, Parul University, Vadodara -391760, Gujarat, India
Mrugesh Suthar Emergency Room Consultant, Parul Sevasharm Hospital, Parul University, Vadodara-391760, Gujarat, India
Ajit K. Gangawane Professor in Biochemistry, Faculty of Applied Sciences, Parul University, Vadodara – 391760, Gujarat, India
Hemantkumar Patadia
hemantsp87@gmail.com
Assistant Professor, Department of Paramedical and Health Sciences, Faculty of Medicine, Parul University, Vadodara -391760, Gujarat, India

Keywords:

COVID-19, metabolic syndrome, diabetes mellitus, hypertension, cardiovascular disease survivors, non-survivors

Abstract

Background: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The goal of this study was to investigate the risk and mortality of COVID-19 patients with Metabolic Syndrome especially during the second wave of pandemic. Methods: This Retrospective Study was conducted by collecting patient records from the COVID-19 registry of Parul Sevasharm Hospital. The record of COVID-19 patients admitted during the second wave of pandemic (April – June, 2021) were included and analyzed for Metabolic syndrome, Demographic characteristics and Clinical Outcomes. Comorbidities were classified into the following Groups: DM (having DM with or without comorbidities), only DM (having DM without other comorbidities); HT (having HT with or without other comorbidities), only HT (having HT without other comorbidities); CVD (having CVD with or without comorbidities), only CVD (having CVD without other comorbidities). Correlation analysis was also done for sub-groups of DM+CVD, CVD+HT, HT+DM, (with or without other comorbidities). Results: Among 994 Patients with COVID-19, 748/994 (75.25%) were discharged as cured and 246 (24.74%) succumbed to death. The mean age of the study population was 52.64±14.72, in which 366 (36.82%) were Females and 628/994 (63.57%) were Males.

Downloads

Download data is not yet available.

References

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Rabilero, A. C., Sabatés, H. R. . R., Martínez, N. G., & Sánchez, J. I. R. (2020). Motivation: a way to enhance young people’s participation in sports-recreational activities. International Journal of Health & Medical Sciences, 3(1), 54-59. https://doi.org/10.31295/ijhms.v3n1.147

Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P. Comorbidity and its Impact on Patients with COVID-19. 2020;1069–76.

Kumar A, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations Awadhesh. Elsevier. 2020;(January).

Rastad H, Karim H, Ejtahed HS, Tajbakhsh R, Noorisepehr M, Babaei M, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabetol Metab Syndr. 2020;12(1):1–11.

Perpiñan C, Bertran L, Terra X, Aguilar C, Lopez-Dupla M, Alibalic A, et al. Predictive biomarkers of COVID-19 severity in SARS-CoV-2 infected patients with obesity and metabolic syndrome. J Pers Med. 2021;11(3).

Roncon L, Zuin M, Rigatelli G, Zuliani G. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information . 2020;(January).

Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis Jing. ijid. 2020;

Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system inhibitors. Clin Exp Hypertens. 2020;00(00):656–60.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. jama. 2020;

Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med. 2020;9(10):1–12.

Guo Z, Jiang S, Li Z, Chen S. Metabolic Syndrome “Interacts” With COVID-19. BIO Integr. 2020;1(4):168–77.

Yang YM, Hsu CY, Lai CC, Yen MF, Wikramaratna PS, Chen HH, et al. Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. Sci Rep. 2017;7(1):1–9.

Guan WJ, Liang WH, He JX, Zhong NS. Comorbidity and its Impact on Patients with COVID-19 Adekunle. sn Compr Clin Med. 2020;55(6):1069–76.

Nakajima K. Serious Conditions in COVID-19 Accompanied With a Feature of Metabolic Syndrome. J Clin Med Res. 2020;12(5):273–5.

Deng S, Peng H. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. joutrnal cli Clin Med. 2020;(February).

Luzi L, Radaelli MG. Influenza and obesity : its odd relationship and the lessons for COVID ‑ 19 pandemic. Acta Diabetol. 2020;57(6):759–64.

Kumar P, Sha M, Mehta Y, Kumar S. Diabetic ketoacidosis precipitated by COVID-19: A report of two cases and review of literature Pavan. elsevier. 2020;(January).

De Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, De Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: A meta-analysis. Diabetol Metab Syndr. 2020;12(1):1–12.

Kim KJ, Kwon TY, Yu S, Seo JA, Kim NH, Choi KM, et al. Ten-Year Mortality Trends for Adults with and without Diabetes Mellitus in South Korea , 2003 to 2013. diabetes metaboism J. 2018;394–401.

Xiong TY, Huang FY, Liu Q, Peng Y, Xu YN, Wei JF, et al. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. Ann Med. 2020;52(7):361–6.